✓an inhibitor of BCR-ABL (IC50 < 30 nM) [279]✓reduces p-RPS6 (S235/236 and S240/244) via the mTOR pathway [103]✓upregulates PDCD4 in BCR-ABL CML cells, while suppressing p-RPS6 (S235/236) and p-p70S6K (T389) [103]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.